Associations of fibroblast growth factor 23 with parameters of phosphate metabolism in incident peritoneal dialysis patients.

dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int 2011; 31:179–88. 2. Paniagua R, Ventura MD, Avila–Díaz M, Cisneros A, Vicenté–Martínez M, Furlong MD, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009; 29:422–32. 3. Han SH, Ahn SV, Yun JY, Tranæus A, Han DS. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2012; 27:2044–50. 4. European Medicines Agency (EMA). Questions and Answers on Endotoxins in Dialysis Solutions Produced at Baxter Manufacturing Plant. London, UK: EMA; 2011. [Available online at: http://www.ema.europa.eu/docs/en_GB/ document_library/Medicine_QA/2011/01/WC500101074. pdf; accessed 30 July 2012] 5. Pérez S, Bertoft E. The molecular structure of starch components and their contribution to the architecture of starch granules: a comprehensive review. Starch/Stärke 2010; 62:389–420. 6. Alsop RM. History, chemical and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14(Suppl 2):S5–12. 7. Robertson S, Huxtable H, Blakemore C, Williams G, Donovan KL. The icodextrin black line sign. Perit Dial Int 2001; 21:621–3. 8. Camilleri B, Glancey G, Pledger D, Williams P. The icodextrin black line sign to confirm a pleural leak in a patient on peritoneal dialysis. Perit Dial Int 2004; 24:197. 9. Sekercioglu N, Jassal SV. Early morning blues—a complication of icodextrin. Perit Dial Int 2004; 24:197–9. 10. Bailey JM, Whelan WJ. Physical properties of starch. I. Relationship between iodine stain and chain length. j Biol Chem 1961; 236:969–73. doi:10.3747/pdi.2012.00171